James W Garrett
Nursing in Salt Lake City, UT
License number
Utah 213772-3102
Issued Date
Mar 19, 1985
Expiration Date
Jan 31, 2019
Category
Nurse
Type
Registered Nurse (Under Interstate Compact)
Address
Address
Salt Lake City, UT
Professional information
James D Garrett, Salt Lake City UT - Lawyer
Address:
Garrett & Garrett
8 E Broadway STE 615, Salt Lake City 84111
(801) 581-1144
8 E Broadway STE 615, Salt Lake City 84111
(801) 581-1144
Licenses:
Utah - Active 1992
Education:
Willamette University College of Law
Calcium Receptor-Active Molecules
US Patent:
5688938, Nov 18, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/485588
Inventors:
Edward M. Brown - Milton MA
Forrest H. Fuller - Salt Lake City UT
Steven C. Hebert - Wellesley MA
James E. Garrett - Salt Lake City UT
Forrest H. Fuller - Salt Lake City UT
Steven C. Hebert - Wellesley MA
James E. Garrett - Salt Lake City UT
Assignee:
The Brigham & Women's Hospital, Inc. - Boston MA
NPS Pharmaceuticals, Inc. - Salt Lake City UT
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
C07K 4705, C12N 1512
US Classification:
536 235
Abstract:
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca. sup. 2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Muo-Conopeptides And Their Use As Local Anesthetics
US Patent:
2004025, Dec 23, 2004
Filed:
Jul 9, 2004
Appl. No.:
10/887203
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
R. McCabe - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Richard Layer - Sandy UT, US
John Wagstaff - Salt Lake City UT, US
Robert Jones - San Diego CA, US
J. McIntosh - Salt Lake City UT, US
R. McCabe - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Richard Layer - Sandy UT, US
John Wagstaff - Salt Lake City UT, US
Robert Jones - San Diego CA, US
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
The present invention is directed to the new O-conopeptides, their coding sequences and their propeptides and to the use of O-conopeptides as a local anesthetic for treating pain. The O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.
Linear Gamma-Carboxyglutamate Rich Conotoxins
US Patent:
2006024, Oct 26, 2006
Filed:
Jun 29, 2006
Appl. No.:
11/476638
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Craig Walker - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Robert Jones - Salt Laker City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Craig Walker - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Robert Jones - Salt Laker City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
A61K 38/16, A61K 38/10, C07K 14/435
US Classification:
514012000, 514013000, 530324000, 530326000
Abstract:
The invention relates to linear y-carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.
Β-Superfamily Conotoxins
US Patent:
7115708, Oct 3, 2006
Filed:
Aug 8, 2005
Appl. No.:
11/198847
Inventors:
Robert M. Jones - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
James E. Garrett - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
James E. Garrett - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
C07K 4/12, A61K 51/08
US Classification:
530324, 424 169
Abstract:
The present invention is directed to β-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the β-superfamily conotoxin peptides and encoding β-superfamily conotoxin propeptides, as well as the β-superfamily conotoxin propeptides.
Linear Gamma-Carboxyglutamate Rich Conotoxins
US Patent:
2003006, Apr 3, 2003
Filed:
Mar 7, 2002
Appl. No.:
10/092367
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake CIty UT, US
Craig Walker - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake CIty UT, US
Craig Walker - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C07K007/08, C07K014/435
US Classification:
530/324000, 530/326000, 530/327000
Abstract:
The invention relates to linear -carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.
Conus Protein Disulfide Isomerase
US Patent:
2004020, Oct 14, 2004
Filed:
Feb 27, 2004
Appl. No.:
10/789450
Inventors:
Grzegorz Bulaj - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US
Olga Buczek - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Ian Goodsell - Sandy UT, US
Baldomero Olivera - Salt Lake City UT, US
Olga Buczek - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Ian Goodsell - Sandy UT, US
Assignee:
Cognetix, Inc. - Salt Lake City UT
International Classification:
C12N009/90, C07H021/04
US Classification:
435/233000, 435/069100, 435/320100, 435/325000, 536/023200
Abstract:
Protein disulfide isomerase is a major component of venom ducts. The invention relates to a protein disulfide isomerase (PDI) from snails, a nucleic acid sequence encoding the protein disulfide isomerase, and to methods for folding disulfide-rich peptides using a protein disulfide isomerase. Oxidative folding of conotoxin precursors, catalyzed by a PDI, was more efficient and decreased the number and concentration of transiently accumulated folding species. The PDI-assisted oxidative folding of conotoxins was also influenced by the propeptide relative to the mature peptide.
Muo-Conopeptides And Their Use As Local Anesthetics
US Patent:
2002019, Dec 26, 2002
Filed:
Jul 20, 2001
Appl. No.:
09/908739
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
R. McCabe - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Richard Layer - Sandy UT, US
John Wagstaff - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
R. McCabe - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Richard Layer - Sandy UT, US
John Wagstaff - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US
Assignee:
COGNETIX, INC. - Salt Lake City UT
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
The present invention is directed to the new O-conopeptides, their coding sequences and their propeptides and to the use of O-conopeptides as a local anesthetic for treating pain. The O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.
Calcium Receptor-Active Molecules
US Patent:
5962314, Oct 5, 1999
Filed:
Oct 3, 1997
Appl. No.:
8/943986
Inventors:
Edward M. Brown - Milton MA
Steven C. Hebert - Wellesley MA
James E. Garrett - Salt Lake City UT
Steven C. Hebert - Wellesley MA
James E. Garrett - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
Brigham and Women's Hospital - Boston MA
Brigham and Women's Hospital - Boston MA
International Classification:
C12N 1563, C12N 1511, C12N 1512, C07K 700
US Classification:
4353201
Abstract:
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca. sup. 2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Mu-Conopeptides
US Patent:
2004019, Sep 30, 2004
Filed:
Apr 21, 2004
Appl. No.:
10/828478
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Lourdes Cruz - Manila, PH
Ki-Joon Shon - Shaker Heights OH, US
Richard Jacobsen - San Francisco CA, US
Robert Jones - Salt Lake City UT, US
G. Cartier - Salt Lake City UT, US
Gregory Shen - Salt Lake City UT, US
John Wagstaff - Salt Lake city UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Lourdes Cruz - Manila, PH
Ki-Joon Shon - Shaker Heights OH, US
Richard Jacobsen - San Francisco CA, US
Robert Jones - Salt Lake City UT, US
G. Cartier - Salt Lake City UT, US
Gregory Shen - Salt Lake City UT, US
John Wagstaff - Salt Lake city UT, US
International Classification:
A61K038/17, C07K014/47
US Classification:
530/324000
Abstract:
The present invention is to -conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the -conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The -conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the -conopeptides and encoding propeptides, as well as the propeptides.